Tags

Type your tag names separated by a space and hit enter

Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1037s-1048s.CC

Abstract

The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses at 33 and 47 months median follow-up showed that anastrozole significantly prolonged disease-free survival and time to recurrence and reduced the incidence of contralateral breast cancer compared with tamoxifen. Results of the completed treatment analysis at 68 months median follow-up confirmed the earlier findings, showing that the absolute difference in disease-free survival continued to increase beyond completion of treatment. Mature safety data from the ATAC trial show that, overall, anastrozole has a favorable safety profile compared with tamoxifen. In the absence of current data on further follow-up or the outcome of trials investigating proactive sequencing of endocrine therapies, we present a model based on several trials, including ATAC. This model suggests that using an aromatase inhibitor as initial adjuvant therapy is a better option than switching to an aromatase inhibitor after >/=2 years of tamoxifen. The relative toxicities of the three approved third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are discussed. These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking.

Authors+Show Affiliations

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. abuzdar@mdanderson.orgNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16467122

Citation

Buzdar, Aman U., and Jack Cuzick. "Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients With Breast Cancer: Emerging Data." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 12, no. 3 Pt 2, 2006, 1037s-1048s.
Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res. 2006;12(3 Pt 2):1037s-1048s.
Buzdar, A. U., & Cuzick, J. (2006). Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 12(3 Pt 2), 1037s-1048s.
Buzdar AU, Cuzick J. Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients With Breast Cancer: Emerging Data. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1037s-1048s. PubMed PMID: 16467122.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. AU - Buzdar,Aman U, AU - Cuzick,Jack, PY - 2006/2/10/pubmed PY - 2006/3/18/medline PY - 2006/2/10/entrez SP - 1037s EP - 1048s JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 12 IS - 3 Pt 2 N2 - The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses at 33 and 47 months median follow-up showed that anastrozole significantly prolonged disease-free survival and time to recurrence and reduced the incidence of contralateral breast cancer compared with tamoxifen. Results of the completed treatment analysis at 68 months median follow-up confirmed the earlier findings, showing that the absolute difference in disease-free survival continued to increase beyond completion of treatment. Mature safety data from the ATAC trial show that, overall, anastrozole has a favorable safety profile compared with tamoxifen. In the absence of current data on further follow-up or the outcome of trials investigating proactive sequencing of endocrine therapies, we present a model based on several trials, including ATAC. This model suggests that using an aromatase inhibitor as initial adjuvant therapy is a better option than switching to an aromatase inhibitor after >/=2 years of tamoxifen. The relative toxicities of the three approved third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are discussed. These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/16467122/Anastrozole_as_an_adjuvant_endocrine_treatment_for_postmenopausal_patients_with_breast_cancer:_emerging_data_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=16467122 DB - PRIME DP - Unbound Medicine ER -